Results 241 to 250 of about 211,078 (328)

Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Aim Integration of locoregional treatments (LRTs) with atezolizumab plus bevacizumab (atezo/bev) has improved treatment outcomes, enabling an increasing number of patients with unresectable hepatocellular carcinoma (HCC) to achieve a complete response (CR). A comprehensive analysis of recurrence following CR may provide insights into prognosis.
Tasuku Nakabori, Masaki Kawabata, Kaori Mukai, Hidenari Hongyo, Noboru Maeda, Makiko Urabe, Yugo Kai, Ryoji Takada, Kenji Ikezawa, Hiroshi Wada, Kunihito Gotoh, Kazuyoshi Ohkawa   +11 more
wiley   +1 more source

Case report: Spatiotemporal HER2 heterogeneity in AFP-producing gastric cancer: navigating long-term survival with molecularly-guided therapy in a refractory case. [PDF]

Front Immunol
Diao Y, Yin H, Sun X, Dong Q, Zhang J.
europepmc   +1 more source

Establishment and Characterization of MCA23, a Novel Mouse Intrahepatic Cholangiocarcinoma Cell Line

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Intrahepatic cholangiocarcinoma (ICC) is an aggressive type of malignancy. Recent advancements have highlighted the importance of the tumor immune microenvironment in therapeutic responses and prognosis. However, the lack of a mouse‐derived ICC cell line and current mouse models limit explorations of the TME in ICC.
Yuchao He, Yi Luo, Liwei Chen, Yu Wang, Bei Liu, Mengting Sun, Wenchen Gong, Xiangdong Tian, Lin Guo, Qin Zhang, Qiang Wu, Lu Chen, Hua Guo   +12 more
wiley   +1 more source

Clinical Characteristics of Patients With Advanced Hepatocellular Carcinoma Who Transitioned to Subsequent Therapies Following Systemic Therapy

Cancer Medicine, Volume 15, Issue 2, February 2026.
Among 136 patients with hepatocellular carcinoma (HCC) receiving first‐line systemic therapy (ST), 66 successfully transitioned to subsequent therapies. favourable ALBI scores, earlier TNM stage at the initiation of ST and treatment with immune checkpoint inhibitors (ICIs) were more likely to progress to subsequent therapies.
Kenji Imai, Koji Takai, Masashi Aiba, Shinji Unome, Takao Miwa, Tatsunori Hanai, Hiroyasu Sakai, Yohei Shirakami, Atsushi Suetsugu, Masahito Shimizu   +9 more
wiley   +1 more source

Hereditary Persistence of Alpha-Fetoprotein and Safe Application of Growth Hormone in Familial Short Stature: A Case Report. [PDF]

Am J Case Rep
Guo S, Zhang J, Chen Q, Yu Y, Ma H.
europepmc   +1 more source

Three‐Year Long‐Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Findings regarding long‐term outcomes of unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab and bevacizumab (Atez/Bev) have yet to be reported. This study was performed to evaluate results regarding 3 year survival of such patients treated in real‐world clinical settings.
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Teruki Miyake, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, on behalf of the RELPEC Group and HCC 48 Group   +55 more
wiley   +1 more source

A review on health system-based surveillance for acute flaccid paralysis: technological advancements, challenges, and outlooks. [PDF]

J Health Popul Nutr
Gemechu H, Biru G, Gebremeskel E, Daba Nemomssa H, Dese K, Wakjira E, Demlew G, Yohannes D, Lemma Abdi K, Murad H, Taye Zewde E, Habtamu B, Tefera M, Alayu M, Workneh Gidi N, Bisrat F, Tadesse T, Kidanne L, Choe SW, Kong J, Ayana G.   +20 more
europepmc   +1 more source

CT and MRI Manifestations of Pancreatic Hemangioma: A Literature Review and a New Case Report

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Pancreatic hemangioma is an extremely rare benign tumor occurring in the pancreas. Preoperative diagnosis is challenging due to its lack of specificity in clinical manifestations and imaging examinations. A pancreatic lesion was found during physical examination of a 54‐year‐old woman who had no symptoms of abdominal discomfort.
Jing Zhang, Jingjing Chen, Dongmei Zou, Xu Cao   +3 more
wiley   +1 more source

Assessment of Circulating Tumor DNA for Early Detection of Hepatocellular Carcinoma in Alpha-Fetoprotein-Negative Patients With Cirrhotic Nodules. [PDF]

JGH Open
Chang LJ, Yu MC, Lee WC, Chan FC, Pan YJ, Tai DI, Su WH.   +6 more
europepmc   +1 more source

Fractionated Gamma Knife Radiation for Papillary Tumor of the Pineal Region: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Papillary tumor of the pineal region (PTPR) is a rare central nervous system neoplasm with an unpredictable clinical course. Gross total resection, the preferred treatment, is often unachievable due to the tumor's deep‐seated location, necessitating alternative therapies.
Arad Iranmehr, Negin Safari Dehnavi, Mohammad Shirani, Reza Samiee, Moein Targhi, Nooshin Banaee, Fatemeh Jafari   +6 more
wiley   +1 more source